Inactive Instrument

BELM PHAR Stock price Nasdaq

Equities

Biotechnology & Medical Research

Sales 2021 6.2M Sales 2022 1.5M Capitalization 834K
Net income 2021 -9M Net income 2022 -25M EV / Sales 2021 * -
Net cash position 2021 * - Net cash position 2022 * - EV / Sales 2022 * -
P/E ratio 2021 *
-
P/E ratio 2022 *
-
Employees -
Yield 2021 *
-
Yield 2022 *
-
Free-Float 98.45%
More Fundamentals * Assessed data
Dynamic Chart
Bellicum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. It has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.
More about the company